ASH 2021 | NGS vs flow cytometry for MRD assessment in NPM1-mutated AML
Farhad Ravandi
• 13 Dec 2021
Farhad Ravandi, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, comments on the rationale and results of a study investigating the best technique to assess measurable residual disease (MRD) in patients with NPM1-mutated acute myeloid leukemia (AML). Dr Ravandi explains that whilst many US centers use next-generation sequencing (NGS) for MRD analysis, it may not be the most sensitive method to measure NPM1 clearance. In fact, the study revealed that flow cytometry is a better assay for sensing MRD in NPM1-mutated AML. This interview took place at the 63rd ASH Annual Meeting and Exposition congress in Atlanta, GA.
